Vaginal atrophy is a prevalent symptom in menopausal women, affecting over 50% of older women and patients with loss of ovarian function. The role of factors other than estrogen, such as the vaginal microbiota (VM), in the development of vaginal atrophy has not been fully explored. Therefore, we selected 8-week-old C57 mice with bilateral ovariectomy for experimentation. After four weeks of treatment, we observed that the vaginal epithelium of ovariectomized mice showed signs of atrophy. There were also significant differences in the structure and metabolites of VM. Vaginal transplantation of microbiota from ovary-intact mice significantly alleviated the vaginal atrophy of ovariectomized mice and altered the structure and metabolism of VM. These findings indicate that ovarian activity significantly affects the structure and metabolism of VM. VM of ovary-intact mice may promote vaginal health by upregulating the estrogen receptor alpha gene (ESR1, one-way ANOVA, F4, 25 = 17.76, P < 0.0001) in vaginal epithelial cells in ovariectomized mice, which in turn promotes cell proliferation (the number of vaginal epithelial cell layers, one-way ANOVA, F4, 25 = 28.04, P < 0.0001). Further studies are needed to investigate the interactions between VM and vaginal health. This finding can help develop new therapeutic strategies and interventions for patients suffering from vaginal atrophy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41598-025-92881-1 | DOI Listing |
Sci Rep
March 2025
The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, P. R. China.
Vaginal atrophy is a prevalent symptom in menopausal women, affecting over 50% of older women and patients with loss of ovarian function. The role of factors other than estrogen, such as the vaginal microbiota (VM), in the development of vaginal atrophy has not been fully explored. Therefore, we selected 8-week-old C57 mice with bilateral ovariectomy for experimentation.
View Article and Find Full Text PDFMaturitas
March 2025
Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, Pisa, Italy. Electronic address:
Objectives: To evaluate the effects of vaginal dehydroepiandrosterone (DHEA) on stress urinary incontinence (SUI) and pelvic floor muscle (PFM) function in postmenopausal women (PMW) suffering from vulvovaginal atrophy (VVA).
Study Design: This prospective observational pilot study included 34 PMW with VVA and moderate SUI. Eligibility criteria included no hormonal therapy nor infections.
Int J Womens Health
March 2025
Department of Obstetrics & Gynecology, Hospital Universitari Sant Joan de Reus, Reus, Spain.
Background: syndrome of menopause (GSM) is a chronic and progressive condition. The adverse events (AEs) and contraindications of hormonal therapy have generated interest in vaginal laser treatment. The non-ablative wavelength 1540 nm (GaAs) in this mixed laser synergistically enhances the 10,600 nm (CO2) effect, providing a deeper hyperthermic stimulation of collagen and elastin without damaging the superficial layers.
View Article and Find Full Text PDFSupport Care Cancer
March 2025
Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Purpose: To improve understanding of genitourinary symptoms (GUS) in women with breast cancer (BC).
Methods: Women with BC completed a survey assessing the type, severity, and impact of GUS experienced, and perceptions of treatment options.
Results: Surveys were completed by 506 women: median age 60 years (range 30 - 83).
J Gynecol Obstet Hum Reprod
February 2025
Department of Gynecological and Breast Surgery and Oncology, Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospital, 75013 Paris, France; Centre de Recherche Saint-Antoine (CRSA), INSERM UMR_S_938, Cancer Biology and Therapeutics, Sorbonne University, 75012 Paris, France; University Institute of Cancer, Sorbonne University, 75013 Paris, France.
The aim of this study was to evaluate the long-term efficacy and adverse effects of fractionated CO2 laser in the treatment of GSM (Genitourinary Syndrome of menopause). This was a retrospective, monocentric, study conducted between January 2017 and July 2023. Forty-six patients receiving 3 sessions of fractional CO2 laser at 4-6 weeks apart were included.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!